Cancer Biological Therapy

Global Cancer Biological Therapy Market to Reach US$173.1 Billion by 2030

The global market for Cancer Biological Therapy estimated at US$121.9 Billion in the year 2024, is expected to reach US$173.1 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$69.9 Billion by the end of the analysis period. Growth in the Cancer Growth Blockers segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$33.2 Billion While China is Forecast to Grow at 9.6% CAGR

The Cancer Biological Therapy market in the U.S. is estimated at US$33.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$35.5 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global "Cancer Biological Therapy" Market – Key Trends & Drivers Summarized

How Is Biological Therapy Transforming The Cancer Treatment Paradigm?
Cancer biological therapy represents a pivotal shift from traditional chemotherapies to more targeted and immune-based approaches, leveraging the body`s natural mechanisms or engineered biological agents to combat cancer cells. These therapies include monoclonal antibodies, cytokine therapies, cancer vaccines, oncolytic viruses, and CAR-T cell therapies. Unlike cytotoxic drugs, biological therapies offer precision targeting, potentially reducing collateral damage to healthy tissues and improving patient quality of life. With rising global cancer incidence, there`s a pressing need for treatments that go beyond broad-spectrum options—particularly for refractory and metastatic cancers. Biologics are proving effective across a range of malignancies including lymphomas, melanoma, breast cancer, and lung cancer. The integration of diagnostics and biomarkers into treatment decisions has enabled biological therapies to be tailored to genetic profiles, increasing their success rates. Combination therapies involving checkpoint inhibitors and monoclonals are also opening new frontiers. Moreover, immunotherapy—an important subset of biological therapy—is rapidly becoming a first-line option in many countries, signaling a fundamental evolution in oncology treatment strategy.

What Scientific Innovations Are Expanding The Therapeutic Reach Of Biologics?
The cancer biological therapy landscape is being redefined by breakthroughs in cell engineering, genetic editing, and antibody development. The advent of bispecific antibodies, which can simultaneously bind to cancer cells and T-cells, is creating potent new treatment modalities. CAR-T cell therapy, initially used in hematologic malignancies, is being adapted for solid tumors through improved tumor-targeting and persistence technologies. Personalized neoantigen vaccines are being developed to boost immune recognition of tumor-specific mutations. Synthetic biology is enabling programmable immune cells with built-in safety switches and dual-function mechanisms. CRISPR gene editing is being used to enhance the performance of adoptive cell therapies, minimizing immune escape by tumors. Additionally, advances in protein engineering are yielding antibody-drug conjugates (ADCs) that combine high specificity with powerful cytotoxic payloads. AI-driven predictive modeling is facilitating the design of biologics with optimized pharmacokinetics and minimal toxicity. These innovations are not just expanding the types of cancers that can be treated but are also enabling therapy development that is faster, more cost-effective, and more targeted than ever before.

How Are Regulatory Shifts And Patient Demands Reshaping Cancer Biologics?
The regulatory landscape for cancer biological therapies is undergoing transformation to keep pace with innovation, leading to faster approval pathways like FDA’s Breakthrough Therapy and EMA’s PRIME designations. Accelerated approvals for drugs such as checkpoint inhibitors and CAR-T therapies underscore the urgency and impact of these treatments. However, regulators are also enforcing stringent post-market surveillance and real-world evidence requirements due to the complexity and novelty of biologics. Patient advocacy has become a force in shaping treatment access, with increasing pressure on healthcare systems to subsidize or reimburse cutting-edge therapies. The rise of value-based healthcare is prompting payers to assess outcomes-based models for biologics reimbursement. In parallel, there`s increasing emphasis on diversity in clinical trials, particularly for immunotherapies, which can behave differently across populations. Ethical considerations around gene-modified therapies are also leading to stricter oversight in manufacturing and consent protocols. Furthermore, the growing role of companion diagnostics in therapy selection is pushing biologics companies to partner closely with diagnostic firms to co-develop biomarker-led strategies. This holistic regulatory-patient dynamic is accelerating innovation while demanding higher transparency and safety.

The Growth In The Cancer Biological Therapy Market Is Driven By Several Factors…
…including rising cancer prevalence, increased adoption of personalized medicine, and growing investment in immuno-oncology pipelines. Demand is surging for biologics in difficult-to-treat cancers, particularly those resistant to standard chemotherapy or radiation. The success of PD-1/PD-L1 inhibitors and CAR-T cell products has spurred a wave of biotech and pharma investment in next-gen immunotherapies. Pharmaceutical giants are expanding their biological portfolios through acquisitions, while governments are funding cancer research through public-private partnerships. In developing regions, the rollout of healthcare infrastructure is increasing access to advanced therapies, supported by rising awareness and early diagnosis initiatives. Trends in consumer behavior show patients increasingly seeking therapies with fewer side effects and longer remission durations. The expansion of clinical trials globally, especially in Asia-Pacific, is facilitating the entry of biologics into new cancer subtypes and indications. Tele-oncology and digital health platforms are enhancing patient management and follow-up, supporting biologic adherence and outcomes tracking. Together, these drivers are forging a robust foundation for the continued evolution of the cancer biological therapy market.

SCOPE OF STUDY:

The report analyzes the Cancer Biological Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Monoclonal Antibodies, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokines, Vaccines); Administration Route (Oral Administration, Injectable Administration)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AbbVie Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Incyte Corporation
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A.
• Seattle Genetics, Inc. (Seagen Inc.)
• Takeda Pharmaceutical Company Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.